Akebia Q1 net loss $26.2M; Auryxia revenue $34.8M; vadadustat approved in 32 countries

Akebia Therapeutics, Inc.

2023-Q1 EPS reported -$0.14 revenue$40,127,000

Net loss of $26.2M improved from $62.4M in Q1 2022; total revenue $40.1M vs $61.7M.
Auryxia net product revenue $34.8M, down 15.9% YoY; company reaffirms 2023 guidance $175-180M.
European Commission approved Vafseo (vadadustat) for anemia in CKD dialysis patients; approved in 32 countries.
Expects FDA Formal Dispute Resolution response within next 30 days; positive alternative dosing study results.
Cash $57.0M; expects to fund operations for at least 12 months with cash and Auryxia revenue.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $40.1 million, net income $(26.2) million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $40.1 million
Net income: $(26.2) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue was $40.1 million in the first quarter of 2023 compared to $61.7 million for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-137689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.